Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19215054 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19196922 | AZITHROMYCIN PREMIX FORMULATION AND PRODUCT, METHODS OF PREPARING SAME, AND METHODS OF USING SAME | May 2025 | September 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19193361 | NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF IN INTRAVENOUS FORMULATIONS AND METHODS OF USE THEREOF | April 2025 | January 2026 | Allow | 8 | 2 | 0 | No | No |
| 19025101 | CRYSTAL FORMS OF BETA-NICOTINAMIDE MONONUCLEOTIDE | January 2025 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18964637 | GLYCOSYLATION METHOD INVOLVING TRIVALENT IODINE REAGENT | December 2024 | February 2025 | Allow | 2 | 0 | 0 | No | No |
| 18833747 | ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS | July 2024 | November 2025 | Allow | 15 | 2 | 0 | No | No |
| 18664971 | CD206 TARGETED DRUG DELIVERY VEHICLES CARRYING NOVEL BISPHOSPHONATE DRUG PAYLOADS VIA A DEGRADABLE LINKER | May 2024 | January 2025 | Allow | 8 | 1 | 0 | No | No |
| 18602969 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | March 2024 | October 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18583315 | METHOD OF PREVENTING OF SYSTEMIC-TO-PULMONARY-ARTERY SHUNT THROMBOSIS | February 2024 | August 2025 | Allow | 18 | 1 | 0 | No | No |
| 18442232 | SYNERGISTIC FORMULATIONS OF ADENOSINE RECEPTOR MODULATING AGENTS AND ANTICHOLINERGICS | February 2024 | June 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18425648 | ALTERING CANCER CELLULAR FUNCTIONS THROUGH PROTON MOPPING | January 2024 | June 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18425707 | METHODS FOR TREATING ALZHEIMER’S DISEASE | January 2024 | July 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18394488 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | December 2023 | September 2025 | Abandon | 21 | 3 | 0 | Yes | No |
| 18519408 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | November 2023 | February 2025 | Allow | 15 | 1 | 0 | No | No |
| 18519667 | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDE RIBOSIDE OR NAD+ PRECURSOR | November 2023 | August 2025 | Allow | 21 | 2 | 0 | No | Yes |
| 18516416 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | November 2023 | July 2025 | Allow | 20 | 2 | 0 | No | No |
| 18516459 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | November 2023 | July 2025 | Allow | 19 | 2 | 0 | No | No |
| 18389006 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | November 2023 | April 2025 | Allow | 17 | 1 | 0 | No | No |
| 18388753 | METHODS, KITS, AND COMPOSITIONS FOR PROCESSING EXTRACELLULAR MOLECULES | November 2023 | April 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18476506 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS | September 2023 | May 2025 | Abandon | 20 | 3 | 0 | No | No |
| 18371865 | FORMULATIONS OF PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE DRUGS | September 2023 | March 2025 | Allow | 18 | 1 | 0 | No | No |
| 18459505 | METHOD OF PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULES | September 2023 | February 2026 | Allow | 30 | 0 | 0 | No | No |
| 18548110 | AGRICULTURAL COMPOSITION COMPRISING KASUGAMYCIN | August 2023 | February 2026 | Allow | 29 | 0 | 0 | No | No |
| 18455539 | BETALAIN COMPOSITIONS AND METHODS THEREFOR | August 2023 | October 2025 | Allow | 26 | 2 | 0 | No | No |
| 18228969 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18345357 | METHODS FOR DECREASING THE INCIDENCE OF NECROTIZING ENTEROCOLITIS IN INFANTS, TODDLERS, OR CHILDREN USING HUMAN MILK OLIGOSACCHARIDES | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18199125 | Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones | May 2023 | August 2025 | Allow | 27 | 2 | 0 | No | No |
| 18199120 | Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients | May 2023 | August 2025 | Allow | 26 | 2 | 0 | No | No |
| 18143675 | MAGNETIC BEAD BASED NUCLEIC ACID EXTRACTION SYSTEM | May 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18304061 | COMPOSITIONS AND METHODS OF TREATING ACNE AND PHOTOAGING | April 2023 | February 2025 | Allow | 22 | 2 | 0 | No | No |
| 18131058 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | April 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18030129 | PARENTERAL NUTRITION FORMULATION AND METHODS OF PREPARATION THEREOF | April 2023 | August 2025 | Allow | 29 | 0 | 0 | No | No |
| 18191901 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | March 2023 | November 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18028080 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF A RED BLOOD CELL DISORDER | March 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18125335 | COMPOSITION AND METHOD OF APPLYING SAME TO INCREASE SURVIVAL OF FISH FOLLOWING CATCH-AND-RELEASE SITUATIONS | March 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18184288 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | March 2023 | October 2025 | Allow | 31 | 4 | 0 | Yes | No |
| 18183110 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGRADATION | March 2023 | January 2025 | Allow | 22 | 2 | 0 | No | No |
| 18040182 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF AN ANTINEOPLASTIC-INDUCED TOXICITY | February 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18160925 | Indodicarbocyanine Phosphoramidites with Bathochromically Shifted Absorption and Emission, and Tunable Hydrophobicity | January 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18157545 | NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF | January 2023 | May 2025 | Abandon | 28 | 2 | 0 | Yes | No |
| 17927478 | USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE | November 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 17927589 | THERAPEUTIC AGENT FOR AN RNA VIRUS INFECTION COMPRISING A COMBINATION OF A PYRAZINE DERIVATIVE AND A THIOPURINE DERIVATIVE | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17998644 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | November 2022 | March 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17923784 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17918964 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17996083 | BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E | October 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17995793 | METHODS, COMPOSITIONS, AND DOSING REGIMENS FOR TREATMENT OF SARS-COV-2 INFECTIONS | October 2022 | July 2025 | Allow | 33 | 0 | 0 | No | No |
| 17915783 | COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2 | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17907160 | COMPOSITIONS AND METHODS CONTAINING N-ACETYLCYSTEIN AND NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | September 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17912933 | COMPOSITION OF ANTIVIRAL AGENT FOR USE IN PROPHYLACTIC OR POST-EXPOSURE TREATMENT OF INFECTIOUS OR RESPIRATORY DISEASES | September 2022 | February 2026 | Allow | 40 | 1 | 0 | No | No |
| 17945872 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MANAGING CYTOPENIA | September 2022 | October 2023 | Allow | 13 | 3 | 0 | Yes | No |
| 17910220 | TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY | September 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 17905262 | COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | August 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17905210 | COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES AND CONDITIONS | August 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17792484 | PROCESS OF PREPARING NUCLEIC ACID OLIGOMER | July 2022 | May 2025 | Allow | 34 | 0 | 0 | No | No |
| 17791799 | BRIDGED NUCLEOSIDE AND NUCLEOTIDE USING SAME | July 2022 | January 2026 | Allow | 42 | 2 | 0 | No | No |
| 17780390 | MIXTURE OF HMOS FOR IMPROVING THE MICROBIOTA OF PREGNANT WOMEN | May 2022 | September 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17778406 | NUCLEIC ACID PURIFICATION METHOD | May 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17777149 | NUCLEIC ACID SEPARATION METHOD, DETECTION METHOD, NUCLEIC ACID PURIFICATION COLUMN AND METHOD OF PRODUCING SAME | May 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17770520 | GLYCOSIDE COMPOUND, AMIDITE COMPOUND, AND PRODUCTION METHOD FOR POLYNUCLEOTIDE USING SAID COMPOUNDS | April 2022 | August 2025 | Allow | 40 | 1 | 0 | No | No |
| 17767825 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMERS | April 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17763127 | SENOLYTIC AND ANTIINFLAMMATORY PRODRUGS AND METHODS OF USE THEREOF | March 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17641083 | USE OF DNMT INHIBITOR | March 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17681731 | FAST DEPROTECTING N-EXOCYCLIC AMINO CYCLIC HYDROCARBON PROCETING GROUPS FOR NUCLEOSIDE PHOSPHORAMIDITES | February 2022 | December 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 17427134 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | February 2022 | June 2025 | Allow | 46 | 1 | 0 | Yes | No |
| 17638537 | STING INHIBITORS AND THEIR THERAPEUTIC USES | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17753150 | THICKENERS AND NUTRITIONAL PRODUCTS TO PROMOTE SAFE SWALLOWING FOR INDIVIDUALS WITH DYSPHAGIA AND METHODS OF MAKING AND USING SAME | February 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17636794 | A PRODRUG PLATFORM USEFUL TO DELIVER AMINES, AMIDES AND PHENOLS | February 2022 | September 2025 | Allow | 43 | 2 | 0 | No | No |
| 17635140 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | February 2022 | October 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17583378 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17625592 | ENHANCING THE ANTIVIRAL EFFICACY OF RNA VIRUS INHIBITION BY COMBINATION WITH MODULATORS OF PYRIMIDINE METABOLISM | January 2022 | August 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17562327 | METHODS OF USING HUMAN MILK OLIGOSACCHARIDES FOR IMPROVING AIRWAY RESPIRATORY HEALTH | December 2021 | December 2024 | Allow | 36 | 4 | 0 | Yes | No |
| 17620545 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | December 2021 | June 2025 | Allow | 42 | 1 | 0 | No | No |
| 17552750 | NUCLEIC ACID CONJUGATES AND USES THEREOF | December 2021 | July 2025 | Allow | 43 | 3 | 1 | No | No |
| 17619081 | NOVEL COMPOUND DERIVED FROM WATERMELON, AND COMPOSITION USING SAME | December 2021 | July 2025 | Allow | 43 | 1 | 0 | No | No |
| 17595984 | REDUCED NICOTINAMIDERIBOSIDES FOR THE TREATMENT/PREVENTION OF LIVER DISEASE | December 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17614055 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | November 2021 | August 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17613197 | FORMULATIONS OF CYCLIC MACROMOLECULE-BASED NANOPARTICLES ENCAPSULATING SMALL MOLECULES | November 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17595565 | RECYCLE CONTENT CELLULOSE ESTER | November 2021 | August 2025 | Allow | 45 | 2 | 0 | No | No |
| 17531336 | Cellulose Ester Composition and Articles Made Therefrom | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17610121 | POROUS CELLULOSE MICROPARTICLES AND METHODS OF MANUFACTURE THEREOF | November 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17609684 | MATERIALS AND METHODS FOR PRODUCING ARABINOXYLAN COMPOSITIONS | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17606149 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN | October 2021 | April 2025 | Allow | 41 | 1 | 0 | No | No |
| 17603021 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | October 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17594287 | METHODS AND COMPOSITIONS FOR IRREVERSIBLE ENZYME INHIBITION | October 2021 | October 2025 | Allow | 48 | 1 | 0 | No | No |
| 17441087 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | September 2021 | March 2026 | Abandon | 53 | 2 | 0 | No | No |
| 17389152 | APPARATUS, SYSTEM, AND METHOD FOR FACILITATING INTRANASAL TREATMENT OF A PATIENT | July 2021 | May 2025 | Allow | 45 | 1 | 0 | No | No |
| 17363983 | 5'-Cyclo-Phosphonate Modified Nucleotides | June 2021 | May 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17297259 | TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES | May 2021 | July 2025 | Allow | 50 | 2 | 1 | No | No |
| 17267271 | BIOHYBRID PEPTIDOGLYCAN OLIGOMERS | February 2021 | November 2024 | Allow | 45 | 1 | 1 | No | No |
| 17258414 | EXTRACTION OF POLYNUCLEOTIDES | January 2021 | April 2025 | Abandon | 51 | 2 | 1 | No | No |
| 16072647 | URIDINE PHOSPHORAMIDE PRODRUG, PREPARATION METHOD THEREFOR, AND MEDICINAL USES THEREOF | July 2018 | April 2020 | Allow | 20 | 2 | 0 | Yes | No |
| 15895872 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | February 2018 | January 2020 | Allow | 23 | 2 | 0 | No | No |
| 15879802 | DRUG FORMULATIONS | January 2018 | October 2019 | Allow | 20 | 1 | 0 | Yes | No |
| 15814100 | TREATMENT TARGETING ONCOLOGY AND NEURODEGENERATION | November 2017 | September 2019 | Allow | 22 | 0 | 1 | No | No |
| 15556982 | COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING | September 2017 | June 2019 | Allow | 21 | 1 | 0 | No | No |
| 15544344 | COMBINATION OF HYALURONIC ACID AND MACROGOL AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | July 2017 | August 2019 | Allow | 25 | 2 | 0 | No | No |
| 15528056 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | May 2017 | November 2019 | Allow | 30 | 3 | 0 | Yes | No |
| 15488368 | COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR | April 2017 | May 2019 | Allow | 25 | 2 | 0 | Yes | No |
| 15320089 | Composition Comprising a Combination of DNA Methylation Inhibitor and a Vitamin D Receptor Agonist for the Treatment of Drug Resistant Cancer or for the Prevention of Tumor Relapse | December 2016 | September 2018 | Allow | 20 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEWIS, PATRICK T.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LEWIS, PATRICK T works in Art Unit 1691 and has examined 317 patent applications in our dataset. With an allowance rate of 97.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner LEWIS, PATRICK T's allowance rate of 97.2% places them in the 88% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEWIS, PATRICK T receive 1.41 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEWIS, PATRICK T is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a -2.2% benefit to allowance rate for applications examined by LEWIS, PATRICK T. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 41.3% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 62.5% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.1% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 14.5% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.